Valneva’s (VALN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock.

Valneva Price Performance

Valneva stock opened at $7.17 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $582.64 million, a PE ratio of -55.15 and a beta of 1.93. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The stock has a 50-day moving average price of $6.34 and a two-hundred day moving average price of $5.58.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The company had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Analysts expect that Valneva will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.